Author

L. Grove

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Organism:human· 1

Frequent Co-Authors

A. A. Melcher· 1 shared A. Burley· 1 shared A. Dhir· 1 shared A. Lepelley· 1 shared A. Patrikeev· 1 shared A. Rullan· 1 shared B. Bader-Meunier· 1 shared B. Callewaert· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. A. Melcher

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent anti-PD-L1- and anti-NKG2A-based adjuvant immunotherapy

E. C. Patin, P. Nenclares, C. Chan Wah Hak, M. T. Dillon, A. Patrikeev, M. McLaughlin, L. Grove, S. Foo, H. Soliman, J. P. Barata, J. Marsden, H. Baldock, V. Roulstone, J. Kyula, A. Burley, , K. J. Harrington

This study combines ATR inhibition with radiotherapy and immune checkpoint blockade to enhance antitumour immunity in HNSCC preclinical models.

bioRxiv · Nov 8, 2023 · PreprintImmunology

Enhanced cGAS-STING-dependent interferon signaling associated with mutations in ATAD3A

A. Lepelley, E. Della Mina, E. Van Nieuwenhove, L. Waumans, S. Fraitag, G. I. Rice, A. Dhir, M.-L. Fremond, M. P. Rodero, L. Seabra, E. Carter, C. Bodemer, D. Buhas, B. Callewaert, P. de Lonlay, , Y. J. Crow

The paper identifies mutations in ATAD3A causing enhanced type I interferon signaling in patients with neurological and autoimmune features.

bioRxiv · Apr 2, 2021Immunology